Cytokines in the immunopathology of systemic sclerosis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Seminars in Immunopathology

• Publication date

  2015-07-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00281-015-0511-7PMID 26152640
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 287. An Observational Study of Intravenous Immunoglobulin Therapy in the Treatment of Gastrointestinal Involvement in Systemic Sclerosis

  2015cited by this paper
• Intravenous Immunoglobulin May Be an Effective Therapy for Refractory, Active Diffuse Cutaneous Systemic Sclerosis

  2015cited by this paper
• Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort

  2015cited by this paper
• Association of Interleukin 1 Family with Systemic Sclerosis

  2014cited by this paper
• Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis

  2014cited by this paper
• Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma

  2014cited by this paper
• Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.

  2014cited by this paper
• Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity.

  2014cited by this paper
• Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients

  2014cited by this paper
• Differential expression of junctional adhesion molecules in different stages of systemic sclerosis.

  2013cited by this paper
• Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin

  2013cited by this paper
• Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma.

  2013cited by this paper
• Agonistic anti-ICAM-1 antibodies in scleroderma: Activation of endothelial pro-inflammatory cascades

  2013cited by this paper
• Targeted therapies for systemic sclerosis

  2013cited by this paper
• Bleomycin inhibits adipogenesis and accelerates fibrosis in the subcutaneous adipose layer through TGF‐β1

  2013cited by this paper
• Interleukin-6: a new therapeutic target in systemic sclerosis?

  2013cited by this paper
• Macitentan and morbidity and mortality in pulmonary arterial hypertension.

  2013cited by this paper
• Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis

  2012cited by this paper
• CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment.

  2012cited by this paper
• Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement

  2012cited by this paper
• Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

  2012cited by this paper
• B cells in systemic sclerosis: a possible target for therapy.

  2011cited by this paper
• Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants

  2011cited by this paper
• Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer

  2011cited by this paper
• Thrombospondin 1 in hypoxia-conditioned media blocks the growth of human microvascular endothelial cells and is increased in systemic sclerosis tissues

  2011cited by this paper
• Fibroblast abnormalities in the pathogenesis of systemic sclerosis

  2011cited by this paper
• Novel insights on the role of the innate immune system in systemic sclerosis

  2011cited by this paper
• Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique.

  2011cited by this paper
• Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

  2011cited by this paper
• Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis

  2011cited by this paper
• Scleroderma Renal Crisis: A Rare but Severe Complication of Systemic Sclerosis

  2011cited by this paper
• Mast cells are a source of transforming growth factor β in systemic sclerosis.

  2011cited by this paper
• Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.

  2011cited by this paper
• Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

  2010cited by this paper
• Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis.

  2010cited by this paper
• Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis

  2010cited by this paper
• Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice

  2010cited by this paper
• Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.

  2010cited by this paper
• Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts.

  2010cited by this paper
• Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis

  2010cited by this paper
• Iloprost modulates the immune response in systemic sclerosis

  2010cited by this paper
• Innovative therapies for systemic sclerosis

  2010cited by this paper
• Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

  2010cited by this paper
• Type I interferon system activation and association with disease manifestations in systemic sclerosis

  2010cited by this paper
• Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.

  2010cited by this paper
• Systemic sclerosis and lupus: points in an interferon-mediated continuum.

  2010cited by this paper
• A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylate

  2009cited by this paper
• Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study

  2009cited by this paper
• Transforming growth factor β as a therapeutic target in systemic sclerosis

  2009cited by this paper
• Sensors of the innate immune system: their mode of action

  2009cited by this paper
• Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.

  2009cited by this paper
• Shifting Our Thinking About Uncommon Disease Trials: The Case of Methotrexate in Scleroderma

  2008cited by this paper
• Mechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis

  2008cited by this paper
• Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension

  2008cited by this paper
• Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension.

  2008cited by this paper
• Imatinib for the treatment of refractory, diffuse systemic sclerosis.

  2008cited by this paper
• Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

  2008cited by this paper
• Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.

  2008cited by this paper
• Cellular and molecular mechanisms of fibrosis

  2008cited by this paper
• Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis.

  2008cited by this paper
• Role of PDGF in fibrotic diseases and systemic sclerosis.

  2008cited by this paper
• Autologous hematopoietic stem cell transplantation for systemic sclerosis

  2008cited by this paper
• Correction: Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

  2008cited by this paper
• Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.

  2008cited by this paper
• Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.

  2008cited by this paper
• High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

  2007cited by this paper
• Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis

  2007cited by this paper
• Systemic sclerosis: a prototypic multisystem fibrotic disorder.

  2007cited by this paper
• High‐dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma

  2007cited by this paper
• Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

  2007cited by this paper
• Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.

  2007cited by this paper
• A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.

  2007cited by this paper
• Increased Bleomycin-Induced Skin Fibrosis in Mice Lacking the Th1-Specific Transcription Factor T-bet

  2007cited by this paper
• Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis.

  2007cited by this paper
• SYSTEMIC SCLEROSIS (SCLERODERMA)

  2007cited by this paper
• Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis

  2007cited by this paper
• Faculty Opinions recommendation of A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

  2007cited by this paper
• A polymorphism in the CTGF promoter region associated with systemic sclerosis.

  2007cited by this paper
• Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

  2007cited by this paper
• Antiangiogenic plasma activity in patients with systemic sclerosis.

  2007cited by this paper
• Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.

  2007cited by this paper
• Historical insights into cytokines

  2007cited by this paper
• Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.

  2006cited by this paper
• Pathogen recognition and innate immunity.

  2006cited by this paper
• Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients.

  2006cited by this paper
• Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension

  2006cited by this paper
• Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo.

  2006cited by this paper
• Intracellular TGF-β Receptor Blockade Abrogates Smad-Dependent Fibroblast Activation In Vitro and In Vivo

  2006cited by this paper
• The logic of TGFβ signaling

  2006cited by this paper
• Cyclophosphamide versus placebo in scleroderma lung disease.

  2006cited by this paper
• [Cellular and molecular mechanisms of fibrosis].

  2006cited by this paper
• The logic of TGFbeta signaling.

  2006cited by this paper
• Bone marrow endothelial progenitors are defective in systemic sclerosis.

  2006cited by this paper
• B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.

  2006cited by this paper
• Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

  2006cited by this paper
• Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines.

  2006cited by this paper
• A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

  2006cited by this paper
• Scleroderma, fibroblasts, signaling, and excessive extracellular matrix

  2005cited by this paper
• Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis

  2005cited by this paper
• Non-Smad TGF-β signals

  2005cited by this paper

• A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways

  2025cites this paper
• Severe fatigue is associated with diminished lung function and elevated Galectin-9 levels in early systemic sclerosis

  2025cites this paper
• Selective JAK-1 inhibitor Upadacitinib and peptide PD29 modulate the JAK and TGF-β/Smad signaling pathways reducing experimental dermal fibrosis.

  2025cites this paper
• IBPA a mutual prodrug of ibuprofen and acetaminophen alleviates inflammation, immune dysregulation and fibrosis in preclinical models of systemic sclerosis.

  2024cites this paper
• Digital ulcers associated with scleroderma: A major unmet medical need

  2024cites this paper
• Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs)

  2023cites this paper
• JAK INHIBITORS IN SYSTEMIC SCLEROSIS: A SCOPING REVIEW

  2023cites this paper
• PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients

  2023cites this paper
• Advances in biological and targeted therapies for systemic sclerosis

  2023cites this paper
• S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin

  2023influential citation
• Effects of upadacitinib and PD29 on oxidative damage and inflammation in bleomycin-induced scleroderma model kidney tissues

  2023cites this paper
• CXCL4-RNA Complexes Circulate in Systemic Sclerosis and Amplify Inflammatory/Pro-Fibrotic Responses by Myeloid Dendritic Cells

  2022cites this paper
• The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review

  2022cites this paper
• JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis

  2022cites this paper
• Mindin is essential for cutaneous fibrogenesis in a new mouse model of systemic sclerosis

  2022cites this paper
• MINDIN (SPONDIN-2) IS ESSENTIAL FOR CUTANEOUS FIBROGENESIS IN A MOUSE MODEL OF SYSTEMIC SCLEROSIS.

  2022cites this paper
• Targeting cytokines and potentiality of JAK–STAT inhibition in systemic sclerosis

  2022cites this paper
• Paclitaxel-induced diffuse scleroderma with possible scleroderma-renal crisis: a case report and literature review of taxanes-induced scleroderma

  2022cites this paper
• JAK inhibitors and systemic sclerosis: A systematic review of the literature.

  2022cites this paper
• The relationship of ocular parameters with clinical parameters and disease‐related quality of life in patients with systemic sclerosis: A cross‐sectional study

  2021cites this paper
• Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin

  2021influential citation
• Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience

  2021influential citation
• Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis.

  2020cites this paper
• JAK Inhibitors: Prospects in Connective Tissue Diseases

  2020influential citation
• Emerging Roles of Matricellular Proteins in Systemic Sclerosis

  2020cites this paper
• Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis

  2020cites this paper
• Role of adipokines in systemic sclerosis pathogenesis.

  2020influential citation
• Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases

  2020cites this paper
• Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods

  2020cites this paper
• Gastrointestinal Involvement in Systemic Sclerosis: Overview, Neglected Aspects, Malnutrition, Body Composition and Management

  2019cites this paper
• Novel Disease-Modifying Drugs against Skin Fibrosis of Systemic Sclerosis

  2019cites this paper
• [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].

  2019cites this paper
• Ocular involvement in systemic sclerosis: A systematic literature review, it's not all scleroderma that meets the eye.

  2019cites this paper
• Systemic Sclerosis in Childhood

  2019cites this paper
• Dexamethasone inhibits cytokine production in PBMC from systemic sclerosis patients

  2019cites this paper
• Gastrointestinal and Hepatic Disease in Systemic Sclerosis.

  2018cites this paper
• Digestive and Hepatic Aspects of the Rheumatic Diseases.

  2018cites this paper
• Transforming growth factor-β signaling in systemic sclerosis

  2018cites this paper
• T cells and cytokines in systemic sclerosis

  2018cites this paper
• Identification of novel targets in fibrosis

  2018cites this paper
• Expression of TLR7, TLR9, JAK2, and STAT3 genes in peripheral blood mononuclear cells from patients with systemic sclerosis

  2017cites this paper
• Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis

  2017cites this paper
• AB0171 Anti-carbamylated protein antibodies in patients with systemic sclerosis: an intriguing association with skin involvement

  2017cites this paper
• Gastro-intestinal Involvement in Systemic Sclerosis

  2017cites this paper
• Serum adipokines levels in patients with systemic sclerosis: A meta-analysis

  2017cites this paper
• Phototherapy in systemic sclerosis: Review

  2017cites this paper
• Treatment of rapidly progressive systemic sclerosis: current and futures perspectives

  2016cites this paper
• Emerging drugs and therapeutics for systemic sclerosis

  2016cites this paper
• Systemic Sclerosis Immunoglobulin Induces Growth and a Pro-Fibrotic State in Vascular Smooth Muscle Cells through the Epidermal Growth Factor Receptor

  2014cites this paper
• JANUS KINASE INHIBITORS IN SYSTEMIC SCLEROSIS: A SCOPING REVIEW

  year unknowncites this paper